FDA staffers question Dyax studies

Staffers at the FDA have raised questions regarding Dyax's ecallantide, an experimental drug intended to treat hereditary angioedema. In a review, the agency workers said that Dyax's studies did not present a clear picture of the drug's effect. And they raised worries about severe allergic reactions recorded during trials. An expert panel is reviewing the drug tomorrow. Report